Prognostic significance of HER2 expression in neuroblastic tumors

Modern Pathology

Volumn 23, Issue 9, 2010, Pages 1261-1268

  Izycka Swieszewska, Ewa ^a   Wozniak, Agnieszka ^a,b   Kot, Jacek ^a   Grajkowska, Wieslawa ^c   Balcerska, Anna ^a   Perek, Danuta ^c   Dembowska Baginska, Bozena ^c   Klepacka, Teresa ^d   Drozynska, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^d INSTITUTE OF MOTHER AND CHILD   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN;

ADOLESCENT; ANTIBODY LABELING; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVOR; CELL DIFFERENTIATION; CELL MATURATION; CHILD; CHILDHOOD CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MITOSIS; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SCHOOL CHILD; TISSUE MICROARRAY; TUMOR CLASSIFICATION; TUMOR LOCALIZATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS;

EID: 77956277946     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.115     Document Type: Article

References (31)

1. Brodeur G. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216.
2. Shimada H, Ambros I, Dehner L, et al. The International Neuroblastoma Pathology Classification (the Shimada System). Cancer 1999;86:364-372.
3. Maris J, Hogarty M, Bagatell R, et al. Neuroblastoma. Lancet 2007;369:2106-2120.
4. Cohn S, Pearson A, London W, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289-297.
5. Fong A, Park J. High-risk neuroblastoma: a therapy in evolution. Pediatr Hematol Oncol 2009;26:539-548.
6. Kokai Y, Cohen J, Drebin J, et al. Stage and tissuespecific expression of the neu oncogene in rat development. Proc Natl Acad Sci 1987;84:8498-8501.
7. Moasser M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26:6469-6487.
8. Chan R, Hardy W, Laing M, et al. The catalytic activity of the ErbB-2 receptor tyrosine kinase is essential for embryonic development. Mol Cell Biol 2002;22:1073-1078.
9. Casalini P, Iorio M, Galmozzi E, et al. Role of HER receptors family in development and differentiation. J Cell Physiol 2004;200:343-350.
10. Shilo B. Regulating the dynamics of EGF receptor signaling in space and time. Development 2005;132: 4017-4027.
11. Baselga J, Swain S. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463-475.
12. Britsch S. The neuregulin-I/ERBB signaling system in development and disease. Adv Anat Embryol Cell Biol 2007;190:1-65.
13. Gilbertson RJ. ErbB2 in pediatric cancer: innocent until proven guilty. Oncologist 2005;10:508-517.
14. Ross J, Fletcher J, Linette G, et al. The Her-2/neu gene and protein in breast cancer: biomarker and target of therapy. Oncologist 2003;8:307-325.
15. Jones KL, Buzdar AL. Evolving novel anti HER2 strategies. Lancet Oncol 2009;10:1179-1187.
16. Salem M, Kinoshita Y, Tajiri T, et al. Association between the HER2 expression and histological differentiation in Wilms tumor. Pediatr Surg Int 2006; 22:891-896.
17. Ensinger C, Prommegger R, Kendler D, et al. HER2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas. Anticancer Res 2003;23: 2349-2353.
18. Brodeur G, Minturn J, Ho R, et al. Trk receptor expression and inhibition in neuroblastoma. Clin Cancer Res 2009;15:3244-3250.
19. Huber K. The sympathoadrenal cell lineage: specification, diversification, and new perspectives. Dev Biol 2006;298:335-343.
20. Goji J, Nakamura H, Ito H, et al. Expression of c-ERbB2 in human neuroblastoma tissues, adrenal medulla adjacent to tumor, and developing mouse neural crest cells. Am J Pathol 1995;146:660-672.
21. Somers G, Ho M, Zielenska M, et al. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Ped Dev Pathol 2005;8:525-532.
22. Lebeau S, Masouye I, Berti M, et al. Comparative analysis of the expression of ERBIN and Erb-B2 in normal human skin and cutaneous carcinomas. Br J Dermatol 2005;152:1248-1255.
23. Ruiz C, Seibt S, Al Kurava K, et al. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 2006;118: 2190-2194.
24. Tuefferd M, Couturier J, Penault-Llorca F, et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PloS ONE 2007;11:e1138.
25. Jakacki R, Hamilton M, Gilbertson R, et al. Pediatric phase I, and pharmacokinetic study of Erlotinib followed by the combination of Erlotinib abd Temozolomide: a childrens oncology group phase I consortium study. J Clin Oncol 2008;26:4921-4927.
26. Ganti R, Skapek S, Zhang J, et al. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Modern Pathol 2006;19:1213-1220.
27. Layfield L, Thompson J, Dodge R, et al. Prognostic indicators for neuroblastoma: stage, grade, DNA ploidy, MIB-1-proliferation index, p53, HER2/neu and EGFR a survival study. J Surg Oncol 1995;59:21-27.
28. Gambini C, Sementa A, Boni L, et al. Expression of HER2/neu is uncommon in human neuroblastic tumors and is unrelated to tumor progression. Cancer Immunol Immunother 2003;52:116-120.
29. Ho R, Minturn J, Hishiki T, et al. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 2005;65:9868-9875.
30. Liu S, Tian Y, Chlenski A, et al. Cross-talk between Schwann cells and neuroblasts influences the biology of neuroblastoma xenografts. Am J Pathol 2005;166:891-900.
31. Krams M, Heidebrecht HJ, Hero B, et al. Repp86 expression and outcome in patients with neuroblastoma. J Clin Oncol 2003;21:1810-1818.